44 results about "Clear cell" patented technology

Disclosed are neocartilage compositions characterized by having multiple layers of cells, said cells being surrounded by a substantially continuous insoluble glycosaminoglycan and collagen-enriched hyaline extra-cellular matrix, and which neocartilage phospholipids are advantageously enriched in anti-inflammatory n-9 fatty acids, particularly 20:3 n-9 eicosatrienoic or Mead acid.Also disclosed are methods of growing neocartilage in substantially serum-free growth media and methods of producing a conditioned growth media containing compounds effective to enhance neocartilage formation.The neocartilage compositions are useful as implants and as replacement tissue for damaged or defective cartilage and as a model system for studying articular cartilage disease and response to natural and synthetic compounds.

The invention discloses a liquid-based cell preservation liquid and a preparation method therefor. Based on the total weight of the cell preservation liquid, the cell preservation liquid comprises the following raw components in parts by weight: 0.05-0.1 parts of a pH buffer, 0.5-1 part of an osmotic pressure retaining agent, 0.3-0.8 parts of a preservative, 25-35 parts of a fixing agent, 0.1-0.6 parts of an anticoagulant, 0.05-0.15 parts of a mucus softener, 0.5-0.9 parts of ammonium chloride and 65-75 parts of de-ionized water. The cell preservation liquid is reasonable in formula, and can effectively keep original morphological structures and physiological functions of cells and effectively remove red blood cell components and mucus components so as to obtain clean field of view; a smear prepared by flaking of an automatic flaking machine is clear and transparent in background and uniform in cell monolayer distribution, thereby facilitating subsequent observation experience of pathologists; and the period of validity of the preservation liquid can reach more than one year.

The invention relates to application of miR-577 for preparing a nephrosis diagnosis marker, in particular to application of miR-577 and a target gene thereof in preparing a renal clear cell carcinomadiagnosis marker. Database renal clear cell carcinoma mRNA (Ribonucleic Acid) and miRNA data are retrieved, and miR-577 and a target gene regulated and controlled by the miR-577 are selected to carryout molecular verification through data integration, differential expression analysis and targeted analysis. A result indicates that the miR-577 and the target genes CD1D, TMEM133 and SLFN11 regulatedand controlled by the miR-577 can serve as the diagnosis marker of the renal clear cell carcinoma, and therefore good clinic application value is performed.

The invention relates to an immune agonist and a composition, applications of the immune agonist and the composition, and a preparation method of the composition. The immune agonist and the composition keep hepatitis B virus specific antibodies of original prophylactic vaccines in animal bodies and human bodies, can inactivate and clear cells infected with hepatitis B viruses, and have double effects of prevention and treatment; and the immune agonist and the composition have stronger immune activation effects than the original HBsAg (Hepatitis B surface antigen), show reinforced immune cell factor induction, higher antibody generating effect and especially high-level mark Th1 type immune generation of gamma-interferon and IgG2a antibodies, and have remarkable innovation and practicability for clearing hepatitis B viruses.

The SCNN1 primer for rapidly diagnosing clear cell nuclear cell carcinoma provided by the invention comprises an internal reference primer pair which is GAPDH, mRNA sequence forward primers and reverse primers of SCNN1A genes with nucleotide sequences shown in SEQ ID NO: 1 and SEQ ID NO: 2, mRNA sequence forward primers and reverse primers of SCNN1B genes with nucleotide sequences shown in SEQ IDNO: 3 and SEQ ID NO: 4, and mRNA sequence forward primers and reverse primers of SCNN1G genes with nucleotide sequences shown in SEQ ID NO: 5 and SEQ ID NO: 6, which take human GAPDH as an internal reference control, and forward primers and reverse primers, having nucleotide sequences shown as SEQ ID NO: 7 and SEQ ID NO: 8. A corresponding kit is also prepared. The kit comprises the following reagents: a tissue lysis solution Trizol, an SYBRGreen Master Mix reaction solution, a reverse transcription reaction solution, a negative control and a positive control. The primer and the kit can eliminate false negative and false positive of clinical sample detection, and are safe, reliable, high in accuracy and suitable for clinical popularization.

A lithographic projection apparatus is provided wherein an object situated in a pulsed beam of radiation has an electrode in its vicinity and a voltage source connected either to the electrode or to the object. This configuration can provide a negative voltage pulse to the object relative to the electrode. The beam of radiation and the voltage pulse from the voltage source are provided in phase or out of phase. In this way, the object is shielded against secondary electrons generated by radiation beam illumination.

The invention relates to a cell for removing amyloid polypeptide and a use thereof. The invention first discloses that the NG2 cell can be activated by A beta and phagocytose A beta. The NG2 cell can be used as a pharmaceutical target for researching and screening a drug for activation or promotion of NG2 phagocytosis on A beta. The NG2 cell provides an effective approach for treating neurodegenerative diseases caused by excess A beta in the brain.

The invention discloses a blood cell separation method for portunus trituberculatus. The method comprises the following steps: diluting iodixanol with an isotonic solution obtained by regulating an osmotic pressure of a PBS buffer solution by utilizing a sodium chloride solution, and performing gradient preparation to obtain three iodixanol solutions of different concentrations; forming gradient solutions of different densities by adopting a cushion technology, and standing to form a continuous density gradient solution to serve as a cell separation solution; collecting blood cells of portunustrituberculatus, and taking mixed cell suspension obtained by diluting the isotonic solution; slowly dropping the mixed cell suspension into the cell separation solution, centrifuging, and dividing the blood cells of portunus trituberculatus into three layers, wherein the uppermost layer refers to clear cells, the intermediate layer refers to small granular cells, and the lowest layer refers to large granular cells. The method has the advantages that only one-step density gradient centrifugation is adopted, the operation is simple, and experiments discover that the separated blood cells haveexcellent viabilities and can be used for cell culture.

The invention discloses a mouse fibroblast and its application. in the field of cell biology. The cell is named mouse fibroblast MFC / HL‑041, and the deposit number is CCTCC NO: C201714. Mouse fibroblasts treated with drug mitogenin C or radiation irradiation are used for the separation and subculture of normal primary epithelial cells and primary tumor cells. The primary epithelial cells of human normal lung and lung cancer thus obtained are observed under a microscope, and they are fresh, densely arranged, with clear cell boundaries, strong three-dimensional sense, and polygonal epithelial cells. It can be used for physiological research of human or animal normal cells, virus infection model of normal cells in vitro, drug sensitivity detection of normal cells in vitro for different drugs, drug screening for individualized treatment of cancer patients and research and development of new anticancer drugs.

The invention discloses an application of acetaldehyde dehydrogenase 2 as a drug target for treating tumor cells with anthracycline type chemotherapy drugs. Drug screening shows that the anthracycline type chemotherapy drugs can specifically kill renal clear cell cancer cells with VHL deletion or mutation and has small toxicity to normal cells, thus providing an effective choice for chemotherapy of renal cancer and overcoming the disadvantage that the renal cancer is only treated through operations in clinical at present. Further study shows the sensitivity of the acetaldehyde dehydrogenase 2 mediated anthracycline type chemotherapy drugs to tumor cells, thus remaindering the application of the acetaldehyde dehydrogenase 2 as the drug target for treating tumor cells with the anthracycline type chemotherapy drugs. Deletion or mutation of the acetaldehyde dehydrogenase 2 exists in 40% of populations in Asia, so that the application of the acetaldehyde dehydrogenase 2 has a broader application prospect. For patients without the deletion or the mutation of the acetaldehyde dehydrogenase 2, killing effects on tumor cells can be significantly enhanced through combination of the anthracycline type chemotherapy drugs and an inhibitor of the acetaldehyde dehydrogenase 2.

The invention discloses an experimental device for recording a detonation cell structure, and a method thereof. The experimental device comprises an ignition bar, a driving segment, a detonation tube,a diaphragm, a flame disturbing spiral and an air inlet. The cell structure is recorded by using a smoke foil technique, a mirror aluminum plate having the advantages of good flexibility, good high temperature resistance and good strength is used as a smoked surface, and the front end of the aluminum plate is trimmed to form an arc shape in order to ensure that the aluminum plate is destroyed inthe detonation process; when smoking is performed, the aluminum plate is first rolled to form a semi-cylindrical shape, then is sealed with a flat plate, and is smoked by a kerosene lamp; the smokingtime of every end of the aluminum plate is controlled to about 5 min in order to obtain the clear cell structure in order to avoid excessive thickness of a smoke film; and after a detonation experiment is performed, condensed water is attached to the surface of the aluminum plate, and the aluminum plate is immediately dried by a hot air blower to prevent liquid drops generated in natural air drying from eroding the cell structure. The clear cell structure is obtained by the low-cost method, so the measurement of the size of the cell is accurate, and reliable experimental data is provided for further completing and developing the theory research of gaseous detonation.